BioCentury | Dec 15, 2017
Preclinical News

A new role for Bcl-XL in fibrosis

...previously used a mitochondrial priming assay to stratify cancer patients into chemotherapy responders and non-responders. Eutropics Pharmaceuticals Inc....
BioCentury | Nov 23, 2015
Company News

Eutropics, Tolero Pharmaceuticals deal

...Eutropics granted Tolero exclusive rights to use Eutropics’ Praedicare-Dx biomarker platform in the development of Tolero’s...
...germ cell tumors. The partners did not respond to inquiries (see BioCentury, Jan. 20, 2014). Eutropics Pharmaceuticals Inc....
BioCentury | Sep 29, 2014
Company News

Eutropics, NIH pharmacogenetics news

...Jan. 20). Eutropics Pharmaceuticals Inc. , Cambridge, Mass. National Institutes of Health , Bethesda, Md. Business: Pharmacogenetics Eutropics...
...Praedicare-Dx biomarker technology for personalized medicine approaches for managing patients with acute myelogenous leukemia (AML). Eutropics...
BioCentury | Jan 20, 2014
Company News

Eutropics, Tolero Pharmaceuticals deal

...The companies partnered to use Eutropics' Praedicare-Dx biomarker platform to predict responses to Tolero's compounds to...
...to carry out clinical correlation studies of alvocidib in combination with cytarabine in AML patients. Eutropics...
...negotiation rights with respect to manufacturing the product for Tolero and becoming a commercialization partner. Eutropics Pharmaceuticals Inc....
BioCentury | Jun 24, 2013
Clinical News

PraediCare Dx: Data

...in Chicago. Eutropics said it plans to complete validation studies of the test in 4Q13. Eutropics Pharmaceuticals Inc....
BioCentury | Dec 15, 2011
Tools & Techniques

Priming chemo prediction

...predicts patient response to chemotherapy by directly measuring how prone cells are to apoptosis. 1 Eutropics Pharmaceuticals Inc....
...Results were published in Science . Clinical utility Letai has exclusively licensed the assay to Eutropics...
...member called myeloid cell leukemia sequence 1 (MCL1). Michael Cardone, cofounder, president and CEO of Eutropics...
BioCentury | Mar 17, 2011
Targets & Mechanisms

MCL1's resistance story

...in combination therapies," said Anthony Letai, cofounder and chairman of the scientific advisory board for Eutropics Pharmaceuticals Inc....
...BCL2, BCL-X L and BCL2-like 2 ( BCL2L2 ; BCLW ). Zeroing in on MCL1 Eutropics...
...Boston, Mass. Brigham and Women's Hospital , Boston, Mass. Dana-Farber Cancer Institute , Boston, Mass. Eutropics Pharmaceuticals Inc....
BioCentury | Oct 29, 2009
Distillery Techniques

Technology: Markers

...Mcl-1- and BCL2-dependent cancers; profiling technology licensed to Eutropics Pharmaceuticals Inc.; profiling technology available for licensing from Eutropics...
Items per page:
1 - 8 of 8
BioCentury | Dec 15, 2017
Preclinical News

A new role for Bcl-XL in fibrosis

...previously used a mitochondrial priming assay to stratify cancer patients into chemotherapy responders and non-responders. Eutropics Pharmaceuticals Inc....
BioCentury | Nov 23, 2015
Company News

Eutropics, Tolero Pharmaceuticals deal

...Eutropics granted Tolero exclusive rights to use Eutropics’ Praedicare-Dx biomarker platform in the development of Tolero’s...
...germ cell tumors. The partners did not respond to inquiries (see BioCentury, Jan. 20, 2014). Eutropics Pharmaceuticals Inc....
BioCentury | Sep 29, 2014
Company News

Eutropics, NIH pharmacogenetics news

...Jan. 20). Eutropics Pharmaceuticals Inc. , Cambridge, Mass. National Institutes of Health , Bethesda, Md. Business: Pharmacogenetics Eutropics...
...Praedicare-Dx biomarker technology for personalized medicine approaches for managing patients with acute myelogenous leukemia (AML). Eutropics...
BioCentury | Jan 20, 2014
Company News

Eutropics, Tolero Pharmaceuticals deal

...The companies partnered to use Eutropics' Praedicare-Dx biomarker platform to predict responses to Tolero's compounds to...
...to carry out clinical correlation studies of alvocidib in combination with cytarabine in AML patients. Eutropics...
...negotiation rights with respect to manufacturing the product for Tolero and becoming a commercialization partner. Eutropics Pharmaceuticals Inc....
BioCentury | Jun 24, 2013
Clinical News

PraediCare Dx: Data

...in Chicago. Eutropics said it plans to complete validation studies of the test in 4Q13. Eutropics Pharmaceuticals Inc....
BioCentury | Dec 15, 2011
Tools & Techniques

Priming chemo prediction

...predicts patient response to chemotherapy by directly measuring how prone cells are to apoptosis. 1 Eutropics Pharmaceuticals Inc....
...Results were published in Science . Clinical utility Letai has exclusively licensed the assay to Eutropics...
...member called myeloid cell leukemia sequence 1 (MCL1). Michael Cardone, cofounder, president and CEO of Eutropics...
BioCentury | Mar 17, 2011
Targets & Mechanisms

MCL1's resistance story

...in combination therapies," said Anthony Letai, cofounder and chairman of the scientific advisory board for Eutropics Pharmaceuticals Inc....
...BCL2, BCL-X L and BCL2-like 2 ( BCL2L2 ; BCLW ). Zeroing in on MCL1 Eutropics...
...Boston, Mass. Brigham and Women's Hospital , Boston, Mass. Dana-Farber Cancer Institute , Boston, Mass. Eutropics Pharmaceuticals Inc....
BioCentury | Oct 29, 2009
Distillery Techniques

Technology: Markers

...Mcl-1- and BCL2-dependent cancers; profiling technology licensed to Eutropics Pharmaceuticals Inc.; profiling technology available for licensing from Eutropics...
Items per page:
1 - 8 of 8